Every 8-K that InMed Pharmaceuticals Inc. (INM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INM filings page.
InMed Pharmaceuticals Inc. (INM) disclosed that on September 16, 2026 it received a Nasdaq notice that the company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in shareholders’ equity for continued listing on The Nasdaq Capital Market. InMed reported $1,075,007 of shareholders’ equity as of June 30, 2026, mainly due to transaction-related expenses for its planned merger with Mentari Therapeutics, Inc., as well as costs from winding down BayMedica, higher general and administrative expenses, intangible asset impairments and ongoing operating losses.
The company expects that completing its merger with Mentari, together with Mentari’s pre-closing financing, will provide the combined company with approximately $490.0 million in aggregate gross proceeds, including $50.0 million from Mentari convertible notes, and believes this will restore compliance with Nasdaq’s equity requirement. InMed’s share price as of September 18, 2026 is reported to be about $0.68 higher, or roughly 99.8% above the level before the initial merger announcement. InMed has 45 days, until November 2, 2026, to submit a compliance plan, and may receive up to 180 days, until March 15, 2027, to regain compliance, though there is no assurance the plan will be accepted or that any appeal of a delisting decision would succeed.
InMed Pharmaceuticals describes an amendment to Mentari Therapeutics’ pre-closing financing tied to their pending merger. Under Amendment No. 1 to the Securities Purchase Agreement, certain original and new investors agreed to purchase an additional $200 million of Mentari common stock and pre-funded warrants immediately prior to the first merger effective time.
The Additional Shares are priced at 152.80% of the per-share price paid by the original investors, with pre-funded warrants priced at that amount minus $0.0001. This expanded Pre-Closing Financing is expected to extend Mentari’s cash runway into 2029, through Phase 2a readouts for its two PACAP-targeted lead migraine programs, and to support its broader migraine prevention pipeline. Based on the merger exchange ratio, pre-Merger Mentari stockholders are expected to own approximately 98.85% of the combined company and pre-Merger InMed shareholders about 1.15%, with total as-converted and as-exercised common shares around 601,195,812.
InMed Pharmaceuticals Inc. entered into Amendment No. 1 to its Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, refining key aspects of their previously announced all‑stock business combination. The amendment clarifies the sequencing of the contemplated steps, including that InMed will change its name to “Mentari Therapeutics, Inc.” before closing, redomesticate from British Columbia to Nevada on the closing date but before the merger is filed, and complete any required Nasdaq reverse split before the first merger effective time.
The amendment also introduces a defined Company PIPE Amendment to allow potential additional pre‑closing private placement financing for Mentari and sets out how such financing would affect the exchange ratio between the parties. In addition, it confirms the intended U.S. tax treatment, stating that the two merger steps are expected to form a single “reorganization” under Section 368(a) of the Internal Revenue Code, and removes a prior contingency regarding a possible redomestication to the Cayman Islands.
Separately, InMed filed a registration statement on Form S‑4 on July 2, 2026 containing a preliminary joint proxy statement/prospectus and management information circular for the proposed transaction, which has board approval at both companies and is targeted to close in the fourth quarter of 2026, subject to shareholder approvals, effectiveness of the Form S‑4 and other customary conditions.
InMed Pharmaceuticals Inc. has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq confirmed that the company’s common shares closed at or above $1.00 per share for 10 consecutive business days from May 19, 2026 through June 2, 2026.
This closes a prior deficiency notice InMed received in March 2026 after its shares traded below $1.00 for 30 consecutive business days. The company remains listed on Nasdaq and has disclosed the update via an 8-K and accompanying press release.
InMed Pharmaceuticals agreed to merge with privately held Mentari Therapeutics in an all‑stock transaction that will effectively hand control to Mentari and refocus the business on migraine prevention therapies. The deal uses a two‑step merger structure in which Mentari becomes a wholly owned subsidiary and InMed creates non‑voting convertible preferred shares to support the new ownership and governance framework.
Based on the exchange ratio, pre‑merger Mentari stockholders are expected to own about 98.49% of the combined company and pre‑merger InMed shareholders about 1.51%, with Mentari designating post‑closing directors and officers. Closing is conditioned on shareholder and regulatory approvals, Nasdaq listing clearance and a pre‑closing Mentari financing of at least $150 million. In parallel, an oversubscribed private placement of roughly $290 million is expected to fund operations through 2028, supporting Mentari’s MT‑001 and MT‑002 migraine pipelines. Pre‑merger InMed holders will receive contingent value rights tied to any future monetization of InMed’s legacy assets.
InMed Pharmaceuticals Inc. entered into an amending agreement with Armistice Capital Master Fund to change the terms of certain preferred investment options originally issued on October 26, 2023. These options give Armistice the right to purchase up to 278,761 common shares.
The exercise price for these preferred investment options is being reduced from $16.60 per share to $0.80 per share. The options were issued in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and there is no assurance any of the options will be exercised.
InMed Pharmaceuticals reported third quarter fiscal 2026 results and a business update. The company is winding down BayMedica’s commercial operations, its only revenue-generating business segment, which is classified as discontinued operations and expected to be substantially exited before the fiscal year ending June 30, 2026.
For the three months ended March 31, 2026, InMed recorded a net loss of $3.0 million from total operations, compared with $2.1 million a year earlier, as research and development and general and administrative costs increased. Continuing operations generated no revenue, while discontinued commercial operations produced $0.7 million of revenue that is reported separately.
Cash, cash equivalents and short-term investments were $5.2 million as of March 31, 2026, down from $10.8 million on June 30, 2025. The company highlighted preclinical data for its CB1/CB2-targeting candidate INM-901, showing reduced neuroinflammation in advanced 3D human brain organoid models of Alzheimer’s disease, consistent with earlier in vivo and ex vivo findings.
InMed Pharmaceuticals Inc. has amended existing preferred investment options held by Sabby Volatility Warrant Master Fund and affiliates of H.C. Wainwright & Co. to significantly lower their exercise prices. Sabby’s options for up to 2,151,478 common shares were repriced from $2.436 to $0.80 per share.
Preferred investment options held by three Wainwright affiliates for up to 153,236 common shares, previously exercisable at $82.50, $20.75 and $3.2013 per share, were also repriced to $0.80. All of these options were originally issued in private placements under Section 4(a)(2) and Regulation D. The company later issued a press release describing these amendments.
InMed Pharmaceuticals Inc. filed a prospectus supplement and related prospectus on April 3, 2026 for the sale of its common shares under an existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC. These potential sales are made pursuant to a shelf registration statement on Form S-3, which was filed on March 20, 2026 and declared effective on March 30, 2026.
The company also filed a legal opinion from Norton Rose Fulbright Canada LLP as Exhibit 5.1 covering the legality of the common shares issuable under the Sales Agreement and included a related consent as Exhibit 23.1.
InMed Pharmaceuticals received a Nasdaq notice that its common share closing bid price was below the $1.00 minimum for 30 consecutive trading days from February 11 to March 26, 2026, putting it out of compliance with Nasdaq Listing Rule 5550(a)(2).
The company has 180 calendar days from March 27, 2026 to regain compliance by having its closing bid at or above $1.00 for at least 10 consecutive business days. During this period, its shares will continue trading on the Nasdaq Capital Market under the symbol INM if other listing standards are met.
If InMed cannot meet the requirement within this window, it may qualify for an additional 180-day grace period, potentially using a reverse stock split to lift the share price. Failure to comply after the available periods could lead to delisting, though InMed could appeal to a Nasdaq Hearings Panel.
InMed Pharmaceuticals reported new preclinical results for its INM-901 Alzheimer's disease program, showing positive effects in 3D human brain organoid models of neuroinflammation. In these human tissue-like systems, INM-901 produced dose-dependent reductions in key pro-inflammatory markers such as IL-6 and IL-8.
The anti-inflammatory effects in human organoids were consistent with earlier in vivo Alzheimer's models and ex vivo LPS-induced neuroinflammation studies, supporting translation from animals to human-relevant systems. The company plans a pre-IND meeting with the FDA in Q3 2026 and is targeting an IND submission and Phase 1 trial initiation in 2027, subject to regulatory feedback and completion of IND-enabling work.
InMed Pharmaceuticals Inc. outlines its 2026 pharmaceutical development outlook, focusing on two small molecule drug candidates targeting CB1/CB2 receptors. The lead program, INM-901 for Alzheimer’s disease, has generated preclinical data suggesting anti-neuroinflammatory, neuroprotective and neuritogenic effects, along with oral bioavailability and supportive molecular findings.
The company plans a pre-IND meeting with the U.S. Food and Drug Administration for INM-901 in Q3 2026 and aims to complete IND-enabling studies ahead of a targeted Phase 1 clinical trial start in 2027. A second candidate, INM-089 for dry age-related macular degeneration, is progressing through preclinical work, with a planned FDA pre-IND meeting in Q4 2026.
InMed Pharmaceuticals is winding down the commercial operations of its BayMedica subsidiary in response to expected U.S. legislation (H.R. 5371) that would materially harm BayMedica’s rare cannabinoid business. BayMedica is the company’s only revenue-generating commercial segment.
The wind down is expected to be substantially completed by June 30, 2026, with operations continuing in the interim to sell existing products. BayMedica anticipates severance and employee-related costs of about $550,000 and other related expenditures of about $120,000, partly offset by remaining product profits.
After the exit, InMed plans to focus exclusively on its pharmaceutical pipeline, including drug candidates INM-901 for Alzheimer’s disease and INM-089 for dry age-related macular degeneration. Unaudited pro forma financials reclassify BayMedica’s business as discontinued operations.
InMed Pharmaceuticals reported second quarter fiscal 2026 results and updated progress across its neurology and ophthalmology drug pipeline. BayMedica commercial revenue was $0.8 million, down from $1.1 million a year earlier, mainly due to pending U.S. legislation that may restrict rare, non-intoxicating cannabinoids.
The company recorded a quarterly net loss of $2.0 million, improving from a $2.6 million loss last year, as research and development expenses fell to $0.6 million from $0.9 million and general and administrative costs eased slightly. As of December 31, 2025, cash, cash equivalents and short-term investments totaled $7.0 million, down from $11.1 million at fiscal year-end, and are expected to fund operations into the fourth quarter of calendar 2026.
Lead candidate -901 for Alzheimer’s disease showed robust oral bioavailability and no adverse neurological effects in large-animal studies, supporting plans for GLP-enabling work and an IND submission. Dry AMD candidate -089 continues to deliver functional and pathological improvements in preclinical models. However, U.S. Act H.R. 5371 could prohibit key BayMedica products from November 12, 2026, potentially forcing inventory write-offs or even discontinuation of BayMedica’s business, which the company warns would have a material adverse effect on its operations and financial condition.
InMed Pharmaceuticals Inc. reported the results of its 2025 Annual General and Special Meeting of Shareholders held on December 17, 2025. Shareholders elected five directors – Eric A. Adams, Andrew Hull, Nicole Lemerond, Neil Klompas and John Bathery – each receiving between 81.94% and 82.11% of votes cast in favor.
Shareholders also approved the appointment of CBIZ CPAs P.C as InMed’s independent registered public accounting firm until the 2026 annual meeting, with 78.84% of votes for and 21.16% abstaining. A key item, the SEPA Share Issuance Proposal, passed with 65.89% support and 34.11% against, authorizing the potential issuance of 20% or more of the company’s common shares outstanding as of December 13, 2024 under a Standby Equity Purchase Agreement with YA II PN, Ltd., in accordance with Nasdaq Listing Rules 5635(d) and 5635(b). No other matters were voted on.
InMed Pharmaceuticals Inc. reported that on December 12, 2025 it issued a news release discussing the potential impact of U.S. legislation H.R. 5371, the “Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026,” on BayMedica Inc., a subsidiary of the company.
The company states that the news release includes forward-looking information and a cautionary note identifying important factors that could cause actual results to differ materially from those expectations. The news release is provided as Exhibit 99.1 and is incorporated by reference.
InMed Pharmaceuticals Inc. (INM) reported that it has successfully completed pharmacokinetic (PK) studies in large animal models for its Alzheimer’s disease drug candidate, INM-901. PK studies examine how a potential treatment is absorbed, distributed, metabolized, and excreted in the body, and completing this work in larger animals is an important step in the research process before potential human testing. The update was provided as a Regulation FD disclosure, with additional details included in a related news release furnished as an exhibit.
InMed Pharmaceuticals appointed John Bathery to its Board, effective October 14, 2025, and increased the Board size to six members. His term runs until immediately before the company’s 2025 Annual General Meeting. Compensation follows the standard non-employee director program, including an annual retainer of US50,000; he also signed the company’s standard indemnification agreement.
Bryan Baldasare notified the company on October 15, 2025 that he will not stand for re-election at the 2025 Annual General Meeting, citing increasing professional obligations. The company stated there is no disagreement with Mr. Baldasare on matters of operations, policies, or practices.
InMed Pharmaceuticals (INM) reported an administrative update. On October 10, 2025, the company announced the meeting, record date, and related details for its 2025 annual general and special meeting of shareholders, as reflected in a revised submission to Canada’s SEDAR system. The notice was furnished via an 8-K under Item 8.01, with the SEDAR filing listed as Exhibit 99.1.
InMed Pharmaceuticals (INM) appointed Neil Klompas to its board of directors, effective October 9, 2025, and increased the board size to five members. His term runs until immediately before the 2025 Annual General Meeting. The company noted there are no related party transactions or family relationships tied to his appointment.
Klompas will receive non-employee director compensation consistent with company policy, including an annual retainer of US$50,000, with potential additional amounts for committee service. InMed furnished a press release as Exhibit 99.1.
InMed Pharmaceuticals Inc. filed a current report to note that on September 23, 2025 it announced financial results for its fiscal year ending June 30, 2025 and gave a business update. The update covered its pharmaceutical drug development programs and the commercial segment of its wholly owned subsidiary, BayMedica, LLC. The related news release is furnished as Exhibit 99.1 under a Regulation FD disclosure and is not deemed filed or incorporated by reference unless specifically stated in another filing.
InMed Pharmaceuticals Inc. reported that on September 23, 2025 it announced the meeting date, record date and related details for its 2025 annual meeting of shareholders through a filing on Canada’s SEDAR system. The company is making that SEDAR disclosure available to U.S. investors as Exhibit 99.1 to this report.
The company states that the information in this report, including Exhibits 99.1 and 99.2, is being furnished rather than filed under the U.S. securities laws, which limits how it is treated for liability purposes and incorporation by reference into other securities filings.
Form 8-K (Item 7.01 – Regulation FD): InMed Pharmaceuticals (Nasdaq: INM) announced it will present new pre-clinical data from its cannabinoid-based INM-901 program for Alzheimer’s disease at the Alzheimer’s Association International Conference (AAIC) 2025. The disclosure, dated 28 Jul 2025, is being furnished—not filed—so it carries no liability under Exchange Act §18 and will not be automatically incorporated into other SEC filings.
No financial results, guidance, or transactional details accompany the notice; the company simply alerts investors to an upcoming scientific presentation. Exhibit 99.1 (news release) and Exhibit 104 (XBRL cover data) are provided as furnished exhibits.
Because the information is limited to a pipeline update and occurs at the pre-clinical stage, any commercial or financial impact remains undetermined within the filing.
InMed Pharmaceuticals has announced promising new preclinical data for their drug candidate INM-901 on June 24, 2025. The research demonstrates significant reduction in inflammation in ex vivo models of neuroinflammation, strengthening the compound's potential as a therapeutic treatment for Alzheimer's disease.
Key points from the 8-K filing:
- The announcement falls under Regulation FD Disclosure (Item 7.01)
- The company is classified as an emerging growth company
- Common shares trade on Nasdaq under symbol INM
- The disclosure is being furnished rather than "filed" under SEC regulations
This development represents a significant milestone in InMed's neurodegenerative disease pipeline, though specific efficacy data and trial details were not disclosed in the filing. The news was signed off by President & CEO Eric A Adams.